Editorial
Nature Biotechnology 26, 715 (2008)
doi:10.1038/nbt0708-715
The other path for follow-ons
Abstract
With follow-on biologics essentially dead in the water in the US, the decision of the world's largest generics manufacturer to invest in a platform for enhancing protein pharmacokinetics could pay dividends.
